Targeted treatments for multiple myeloma: specific role of carfilzomib

Item

http://www.wikidata.org/entity/Q26996524

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeted treatments for multiple myeloma: specific role of carfilzomib

@ast

Targeted treatments for multiple myeloma: specific role of carfilzomib

@en

Targeted treatments for multiple myeloma: specific role of carfilzomib

@nl

type

Item

label

Targeted treatments for multiple myeloma: specific role of carfilzomib

@ast

Targeted treatments for multiple myeloma: specific role of carfilzomib

@en

Targeted treatments for multiple myeloma: specific role of carfilzomib

@nl

prefLabel

Targeted treatments for multiple myeloma: specific role of carfilzomib

@ast

Targeted treatments for multiple myeloma: specific role of carfilzomib

@en

Targeted treatments for multiple myeloma: specific role of carfilzomib

@nl

P1476

Targeted treatments for multiple myeloma: specific role of carfilzomib

@en

P2093

Dhivya Sugumar

http://www.w3.org/2001/XMLSchema#string

Jesse Keller

http://www.w3.org/2001/XMLSchema#string

Ravi Vij

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

P304

23-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5066744

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/PGPM.S39085

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272514228

http://www.w3.org/2001/XMLSchema#string

P698

25691814

http://www.w3.org/2001/XMLSchema#string

P932

4325627

http://www.w3.org/2001/XMLSchema#string